Antibiotic prophylaxis with contrimoxazole/colistin similar to ciprofloxacin in acute myeloid leukemia
the ONA take:
Recent meta-analyses showed that incidence of fever and mortality rate were reduced in patients with neutropenia after chemotherapy when antibiotic prophylaxis was administered.
As fluoroquinolones appear to be most effective and well tolerated, a German team changed the antibiotic prophylaxis regimen used from cotrimoxazole/colistin (COT/COL) to ciprofloxacin (CIP) in patients with acute myeloid leukemia (AML).
In this retrospective study, they compare the efficacy and development of bacterial resistance with the two prophylaxis regimens over a period of more than 4 years via a standard questionnaire.
The findings show no significant difference in incidence of fever between the COT/COL group and the CIP group.
In addition, the rates of both microbiologically and clinically documented infections were similar, as well as rates of gram-positive and gram-negative bacteria.
No increases in resistance rates or cases with Clostridium difficile-associated diarrhea in the CIP group were noted.
The researchers conclude antibiotic prophylaxis with CIP and COT/COL in patients with AML was similarly effective with no increase in bacterial resistance.
Antibiotic prophylaxis regimen used from cotrimoxazole/colistin (COT/COL) to ciprofloxacin (CIP) in patients with AML.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Breast Cancer Diagnosis and Nurse Navigation Survey
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|